Jaime F. Modiano

Has grant

Alvin & June Perlman Professor of Animal Oncology

University of Minnesota
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Translation of a novel combination therapy approach for non-Hodgkin lymphoma

Open Date: 2022-09-01

Close Date: 2027-08-31

Grant: Close

A Novel Approach Combining Oncolytic Virotherapy and Dual Immune Checkpoint Blockade for Metastatic Osteosarcoma

Open Date: 2020-09-01

Close Date: 2022-08-31

Grant: Close

Novel Immunotherapy for Sarcomas using Combination Oncolytic VSV and IL-18 Superkine

Open Date: 2019-02-01

Close Date: 2022-01-31

Grant: Close

Mechanisms of Resistance to Immunotherapy in Osteosarcoma

Open Date: 2016-10-01

Close Date: 2017-09-01

Grant: Close

(PQ3) Modulation of Osteosarcoma Biology by Inflammation and Immunity Defined through a ComparativeApproach

Open Date: 2016-09-01

Close Date: 2018-08-31

Articles (14)

Purpose: Comprehensive molecular profiling was used to define the genomic and immune landscapes of leiomyosarcomas (LMS) by anatomic subtypes, which have not been completely characterized. Experimental Design: A total of 1,115 LMS samples, categorized into uterine LMS (uLMS), retroperitoneal LMS, or other LMS (oLMS), underwent DNA/RNA sequencing (Caris Life Sciences). Genomic/transcriptomic profiles were compared across subtypes. Immune profiling was compared with melanoma ( n = 1,255), an immunogenic tumor. Insurance claims data were used to infer real-world outcomes with immune checkpoint inhibitors (ICI) in LMS. Results: uLMSs ( n = 701) were molecularly distinct from retroperitoneal LMSs ( n = 166) and oLMSs ( n = 248). RB1 mutations and MAP2K4 copy-number amplification were more common in non-uLMS. MED12 mutations were almost exclusive to uLMS. Traditional ICI response biomarkers (i.e., PD-L1) did not vary by anatomic site. Non-uLMS demonstrated upregulated immune-related gene sets, including IFN and inflammatory response pathways, and higher immune cell infiltration, especially CD8 + T cells and B cells (>2-fold increase, P n = 138), 29% of patients with LMS receiving ICI were treated >6 months, indicating potential clinical benefit. Conclusions: Comprehensive profiling suggested that uLMS represents a molecularly distinct disease from non-uLMS. Although traditional ICI response biomarkers were similar across anatomic subtypes, uLMSs were immune cold compared with non-uLMS. Signals for ICI responsiveness, such as high TIS and immune cell abundance, in some tumors suggest that further research into immunotherapies for LMS is warranted.

Year:

2025

Hematopoietic expansion derived from adoptive transplantation of canine hemangiosarcoma in immunodeficient mice. A and B , Xenotransplantation of canine hemangiosarcoma cell lines created exuberant myeloid hyperplasia in mouse spleens. Representative photomicrographs show histopathology by H&E staining of spleens from NSG mice transplanted with hemangiosarcoma cell lines SB (A) and EFB (B). C, Immunoreactivity of anti-mouse Ki-67 (Tec-3) antibody shows strongly positive signal in proliferating cells in the spleen. D, Immunostaining of anti-human (and canine cross-reactive) Ki-67 (MiB-1) antibody shows lack of positive staining among proliferating cells. E, The proliferating cells are immunoreactive with anti-mouse Ter-119 antibody. F, SB cells expressing Luciferase are detected in mouse spleen (arrows). Images shown in C, D, E, and F are from IHC staining done in mice inoculated with SB cells modified to express GFP and firefly Luciferase. Horseradish peroxidase (for Ki-67 stains) and alkaline phosphatase (for Ter-119 and Luciferase) conjugates were used. Counterstain = hematoxylin. A–D: Bar = 200 µm; E–F: Bar = 50 µm.

Year:

2024

Hemangiosarcoma and angiosarcoma are soft-tissue sarcomas of blood vessel–forming cells in dogs and humans, respectively. These vasoformative sarcomas are aggressive and highly metastatic, with disorganized, irregular blood-filled vascular spaces. Our objective was to define molecular programs which support the niche that enables progression of canine hemangiosarcoma and human angiosarcoma. Dog-in-mouse hemangiosarcoma xenografts recapitulated the vasoformative and highly angiogenic morphology and molecular characteristics of primary tumors. Blood vessels in the tumors were complex and disorganized, and they were lined by both donor and host cells. In a series of xenografts, we observed that the transplanted hemangiosarcoma cells created exuberant myeloid hyperplasia and gave rise to lymphoproliferative tumors of mouse origin. Our functional analyses indicate that hemangiosarcoma cells generate a microenvironment that supports expansion and differentiation of hematopoietic progenitor populations. Furthermore, gene expression profiling data revealed hemangiosarcoma cells expressed a repertoire of hematopoietic cytokines capable of regulating the surrounding stromal cells. We conclude that canine hemangiosarcomas, and possibly human angiosarcomas, maintain molecular properties that provide hematopoietic support and facilitate stromal reactions, suggesting their potential involvement in promoting the growth of hematopoietic tumors. Significance: We demonstrate that hemangiosarcomas regulate molecular programs supporting hematopoietic expansion and differentiation, providing insights into their potential roles in creating a permissive stromal-immune environment for tumor progression.

Year:

2024

Hematopoietic support and stromal regulation of canine hemangiosarcoma cells. A, Flow cytometric data depict populations of cells expressing CD43 and CD45 differentiated from CD34 + hUCB cells. CD34 + hUCB cells were pooled from 2 patients. M2-10B4, hBM-MSCs, and canine hemangiosarcoma cells (DHSA-1426 and EFB) were seeded on gelatin-coated 24-well plates at a density of 1 × 10 5 cells/well. Gelatin-coated wells without stroma served as a negative control. Surface antigens CD34, CD43, and CD45 were analyzed at week 5. B and C , Bar graphs illustrate number of different colonies formed by hUCB CD34 + cells cocultured with feeder cells. Both DHSA-1426 and EFB canine hemangiosarcoma cell lines expanded hUCB CD34 + cells similarly to the M2-10B4 and hBM-MSC positive control lines, while gelatin-coated wells alone failed to support expansion. Burst-forming unit-erythroid (BFU-E), CFU (colony-forming unit)-Erythroid (CFU-E), CFU-granulocyte/macrophage (CFU-GM), CFU-macrophage (CFU-M), and CFU-granulocyte/erythroid/macrophage/megakaryocyte (CFU-GEMM) were determined for CFU assay.

Year:

2024

Hemangiosarcoma and angiosarcoma are soft-tissue sarcomas of blood vessel–forming cells in dogs and humans, respectively. These vasoformative sarcomas are aggressive and highly metastatic, with disorganized, irregular blood-filled vascular spaces. Our objective was to define molecular programs which support the niche that enables progression of canine hemangiosarcoma and human angiosarcoma. Dog-in-mouse hemangiosarcoma xenografts recapitulated the vasoformative and highly angiogenic morphology and molecular characteristics of primary tumors. Blood vessels in the tumors were complex and disorganized, and they were lined by both donor and host cells. In a series of xenografts, we observed that the transplanted hemangiosarcoma cells created exuberant myeloid hyperplasia and gave rise to lymphoproliferative tumors of mouse origin. Our functional analyses indicate that hemangiosarcoma cells generate a microenvironment that supports expansion and differentiation of hematopoietic progenitor populations. Furthermore, gene expression profiling data revealed hemangiosarcoma cells expressed a repertoire of hematopoietic cytokines capable of regulating the surrounding stromal cells. We conclude that canine hemangiosarcomas, and possibly human angiosarcomas, maintain molecular properties that provide hematopoietic support and facilitate stromal reactions, suggesting their potential involvement in promoting the growth of hematopoietic tumors. Significance: We demonstrate that hemangiosarcomas regulate molecular programs supporting hematopoietic expansion and differentiation, providing insights into their potential roles in creating a permissive stromal-immune environment for tumor progression.

Year:

2024

Gene expression analysis in DHSA-1426 hemangiosarcoma cells and xenograft tumors using RNA-seq data. A, The volcano plot visualizes 2,391 significant DEGs (1,034 upregulated and 1,357 downregulated) in DHSA-1426 cells ( n = 3) compared with nonmalignant endothelial cells ( n = 4; q -value 2 fold change > |2|). The DEGs are indicated by red dots. NS = not significant; log 2 FC = log 2 fold change. B, Gene Ontology enrichment analysis depicts biological processes associated with significant DEGs. P , adjust = adjusted P -value. C, Bar graphs present normalized gene expression values of CSF3 , IL6 , and IL8 in RNA-seq data generated from canine nonmalignant endothelial cells ( n = 4) and DHSA-1426 hemangiosarcoma cells ( n = 3). D, Schematic illustration visualizes the experimental steps for species-specific gene expression analysis of xenograft tumors using RNA-seq data. E, Bar graphs show the expression of mouse-specific genes in RNA-seq data generated from xenograft tumor tissues of canine hemangiosarcoma ( n = 4) and mouse lymphoma ( n = 7). A two-way ANOVA test was conducted to compare the means between groups. ****, P

Year:

2024

Immune cell infiltration and comparative immune signatures between canine hemangiosarcoma and human angiosarcoma. A, A total of 461 upregulated genes were identified in immune-high ( N = 8) compared with immune-low ( N = 5) groups in human angiosarcomas (FDR P value B, 567 immune gene signatures were identified among three molecular subtypes of canine hemangiosarcomas ( N = 76; FDR P value 3). The heat maps show upregulated (red) and downregulated (green) genes by unsupervised hierarchical clustering (average linkage; mean-centered; log 2 transformed). C, Venn diagram shows 58 common genes associated with signaling pathways of immune cell functions between human and canine tumors. Representative photomicrographs of H&E and IHC staining showing histologic morphology and immune cell infiltration in canine hemangiosarcoma ( D ) and human angiosarcoma tissues ( E ) using anti-CD3, anti-PAX5, anti-MAC387, and anti-Iba1 (for canine) or anti-CD163 (for human) antibodies for detecting T cell, B cell, and macrophages. Horseradish peroxidase (counterstain = hematoxylin) or alkaline phosphate (for Iba1; counterstain = methylene blue). Bar = 50 µm. Scatter plots display correlation between transcriptional and IHC immune score in canine hemangiosarcoma ( F ) and human angiosarcoma ( G ). Spearman correlation coefficient ( R ) was calculated.

Year:

2024

Hematopoietic expansion derived from adoptive transplantation of canine hemangiosarcoma in immunodeficient mice. A and B , Xenotransplantation of canine hemangiosarcoma cell lines created exuberant myeloid hyperplasia in mouse spleens. Representative photomicrographs show histopathology by H&E staining of spleens from NSG mice transplanted with hemangiosarcoma cell lines SB (A) and EFB (B). C, Immunoreactivity of anti-mouse Ki-67 (Tec-3) antibody shows strongly positive signal in proliferating cells in the spleen. D, Immunostaining of anti-human (and canine cross-reactive) Ki-67 (MiB-1) antibody shows lack of positive staining among proliferating cells. E, The proliferating cells are immunoreactive with anti-mouse Ter-119 antibody. F, SB cells expressing Luciferase are detected in mouse spleen (arrows). Images shown in C, D, E, and F are from IHC staining done in mice inoculated with SB cells modified to express GFP and firefly Luciferase. Horseradish peroxidase (for Ki-67 stains) and alkaline phosphatase (for Ter-119 and Luciferase) conjugates were used. Counterstain = hematoxylin. A–D: Bar = 200 µm; E–F: Bar = 50 µm.

Year:

2024

Establishment of xenografts derived from canine hemangiosarcoma in immunodeficient mice. A, Schematic illustration depicts process of tumor xenografts in BNX mice. B, DHSA-1426 tumor cell line was established from a canine patient diagnosed with hemangiosarcoma (A). Cells from DHSA-1426 passages 5 (p5) and 14 (p14) formed tumors histologically classified as hemangiosarcoma (B and C). Cells cultured from xenograft-derived tumors developed histologically identical tumors after serial transplantation (D). Both the primary tumor (E) and the xenograft tumor (F) were positive for CD31 IHC staining. A–D, Hematoxylin and eosin (H&E) stain. E and F, IHC with an anti-CD31 antibody (alkaline phosphatase conjugates; counterstain = hematoxylin). Bar = 200 µm. C, FISH images using canine-specific ( CXCL8 , red) and mouse-specific (X chromosome, green) probes in a canine hemangiosarcoma xenograft transplanted into receptive immunodeficient female mouse hosts. Red and green arrows point to representative xenograft canine tumor cells and mouse stromal cells, respectively, to aid in identification. D, Individual points on graph represent relative quantity of donor (dog) and host (mouse) cells in each tumor type. 10–12 fields of pictures at high magnification (400X) per slide were acquired. A total of approximately 1,000 cells in individual xenograft tumor was counted, and the percentages for each species-specific cells are presented. E, Dot plot shows microenvironment scores for 76 primary hemangiosarcoma tissues, estimated using RNA-seq data and xCell algorithm. The red dot indicates a DHSA-1426 tumor tissue used for xenograft.

Year:

2024

Gene expression analysis in DHSA-1426 hemangiosarcoma cells and xenograft tumors using RNA-seq data. A, The volcano plot visualizes 2,391 significant DEGs (1,034 upregulated and 1,357 downregulated) in DHSA-1426 cells ( n = 3) compared with nonmalignant endothelial cells ( n = 4; q -value 2 fold change > |2|). The DEGs are indicated by red dots. NS = not significant; log 2 FC = log 2 fold change. B, Gene Ontology enrichment analysis depicts biological processes associated with significant DEGs. P , adjust = adjusted P -value. C, Bar graphs present normalized gene expression values of CSF3 , IL6 , and IL8 in RNA-seq data generated from canine nonmalignant endothelial cells ( n = 4) and DHSA-1426 hemangiosarcoma cells ( n = 3). D, Schematic illustration visualizes the experimental steps for species-specific gene expression analysis of xenograft tumors using RNA-seq data. E, Bar graphs show the expression of mouse-specific genes in RNA-seq data generated from xenograft tumor tissues of canine hemangiosarcoma ( n = 4) and mouse lymphoma ( n = 7). A two-way ANOVA test was conducted to compare the means between groups. ****, P

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Collaborators (18)

Jong Hyuk Kim

Assistant Professor

University of Florida

UNITED STATES
View details

Don S. Dizon

Tufts Medical Center

UNITED STATES
View details

Troy C. Lund

University of Minnesota

UNITED STATES
View details

Sagar M. Goyal

University of Minnesota

UNITED STATES
View details

Matthew Breen

North Carolina State University

UNITED STATES
View details

Bradley DeNardo

Associate Professor

Brown University

UNITED STATES
View details

Margaret von Mehren

Professor

Fox Chase Cancer Center

UNITED STATES
View details

Timothy O'Brien

Professor

University of Minnesota

UNITED STATES
View details

Susan Bullman

Associate Professor

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Vaia Florou

Associate Professor

Huntsman Cancer Institute

UNITED STATES
View details

Andreas Seeber

Medical University of Innsbruck

AUSTRIA
View details

Ashley Schulte

University of Minnesota

UNITED STATES
View details

Mohd Khushman

Professor

Washington University in St. Louis

UNITED STATES
View details

Jonathan C. Trent

University of Miami Miller School of Medicine

UNITED STATES
View details

Sunil Kumar Mor

Assistant Professor

South Dakota State University

UNITED STATES
View details

DONGHEE LEE

University of Florida

UNITED STATES
View details

Dan Kaufman

Professor

University of California, San Diego

UNITED STATES
View details

Matthew Meyerson

Director, Center for Cancer Genomics

Dana-Farber Cancer Institute

UNITED STATES
View details